Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
      Google Scholar   
Citation:
Transplant Cell Ther vol 29 (3) 174.e1-174.e10
Year:
2023
Type:
Manuscript
Funding:
AFT
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub-ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
12
Parents:
3811  
Children:
None
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
Jansen  
Grants:
 
Corr. Author:
 
Authors:
                                                                           
Networks:
CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TN008, LAPS-TX011, LAPS-TX035, LAPS-UT003, LAPS-WI013, LAPS-WI020, NC002, NE003, NEWMEXICO, OR013   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
AFT-29 (GRIFFIN), MASTER
Phases:
2
Keywords: